NCT03683680Recruiting
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 21 Sept 2018
- Start date
- 31 Oct 2018
- Primary completion date
- 1 Jan 2030
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Mesothelioma
- NCT number
- NCT03683680
What you commit to
- Study type: Interventional
- Planned participants: 240
- From 31 Oct 2018 to the primary completion date, 1 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- surgery,
Other
- -Any patient who is found to be unsuitable for
- treatment
- diagnosis,
Who the study is looking for
- All adult patients with a diagnosis of malignant pleural mesothelioma undergoing
- diagnostic pleural biopsy
- pleuroscopy
- and/or VATS resections
- Participants must be 18 years of age or older.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.